Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
DiaMedica Therapeutics Inc. (DMAC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: " "
05/15/2023 8-K Quarterly results
Docs: " "
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: " "
11/10/2021 8-K Quarterly results
Docs: " "
05/05/2021 8-K Quarterly results
11/13/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
05/13/2019 8-K Quarterly results
Docs: "DiaMedica Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2019 2018 Operating expenses: Research and development 2,607 $ 791 General and administrative 814 515 Total operating expenses 3,421 1,306 Operating loss Other expense: Governmental assistance – research incentives Other expense 35 Change in fair value of warrant liability — 39 Total other income Loss before income tax benefit Income tax expense 9 1 Net loss Other comprehensive income Unrealized gain on marketable securities 3 — Net loss and comprehensive loss $ $ Basic and diluted net loss per share $ $ Weighted average shares outstanding—basic and diluted 11,956,874 6,546,780 DiaMedica Therapeutics Inc. Consolidated Balance Sheets ASSETS Current assets: Cash and cas..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy